banner

Press Release

View printer-friendly version

<<  Back

ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--April 30, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the following investor conferences:

  • Deutsche Bank's 33rd Annual Health Care Conference on Wednesday, May 7, 2008, at 9:30 a.m. Eastern Time at the InterContinental Boston Hotel in Boston.
  • The Bank of America 2008 Health Care Conference on Wednesday, May 14, 2008, at 10:00 a.m. Pacific Time at the Four Seasons Hotel in Las Vegas.
  • The JMP Seventh Annual Securities Research Conference on Monday, May 19, 2008, at 11:00 a.m. Pacific Time at The Ritz-Carlton Hotel in San Francisco.

Live webcasts of these presentations will be accessible on the company's website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website for two weeks following the presentation.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA currently has five mid-to-late stage clinical programs as well as a portfolio of preclinical and discovery assets directed at diseases with large unmet medical needs, including schizophrenia, Parkinson's disease psychosis, sleep maintenance insomnia, and neuropathic pain. All of the drug candidates in ACADIA's product pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA's corporate headquarters is located in San Diego, California and it maintains research and development operations in both San Diego and Malmo, Sweden.

CONTACT: ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and Chief Financial Officer
858-558-2871

SOURCE: ACADIA Pharmaceuticals Inc.